Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
504 questions in 57 reviews · Kidney and Transplant
current versionsNo studies 504 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High vs with low‐dose potassium binder Cardiovascular death · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
High vs with low‐dose potassium binder Cardiac arrhythmia · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
High vs with low‐dose potassium binder HRQoL · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
High vs with low‐dose potassium binder Serum potassium · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Potassium binder vs placebo Cardiac arrhythmia · people with CKD (including haemodialysis) Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) Death (any cause) · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) Cardiovascular death · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) Cardiac arrhythmia · people with CKD Potassium binders for chronic hyperkalaemia in people with chronic kidney disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Extended vs short duration antibiotics Adverse reactions · preventing post‐surgical site infections in solid organ transplant recipients Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients (2020) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs no antibiotics Adverse reactions · solid organ transplant recipients Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients (2020) · Cochrane | no estimate extracted | NR | No studies |
Surgical reimplantation of ureters plus antibiotics vs antibiotics alone Number of UTI with microbial resistance (resistant organisms) · primary VUR Interventions for primary vesicoureteric reflux (2019) · Cochrane | no estimate extracted | NR | No studies |
Macroplastique vs dextranomer/hyaluronic acid polymer (Deflux) to correct vesicoureteric reflux New renal parenchymal defects on DMSA scan (kidney injury) · primary VUR Interventions for primary vesicoureteric reflux (2019) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs antibiotic prophylaxis Resolution of VUR · primary VUR Interventions for primary vesicoureteric reflux (2019) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs antibiotic prophylaxis Adverse events · primary VUR Interventions for primary vesicoureteric reflux (2019) · Cochrane | no estimate extracted | NR | No studies |
Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney… (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive‐behavioural therapy vs usual care Major depression Mini International Neuropsychiatric Interview (MINI) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Counselling vs usual care HRQoL Kidney Disease Quality of Life (KDQOL‐36) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Counselling vs usual care Anxiety · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Counselling vs usual care Withdrawal from dialysis · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Counselling vs usual care Withdrawal from intervention (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs usual care Anxiety Hospital Anxiety and Depression Scale (HADS) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs usual care Withdrawal from dialysis · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs usual care Withdrawal from intervention · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs usual care Death (any cause) · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care Major depression · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care HRQoL Investigators measured health‐related quality of life using the Health Status Questionnaire Short Form (SF‐36) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care Anxiety · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care Withdrawal from dialysis · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care Withdrawal from intervention · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Relaxation techniques vs usual care Death (any cause) · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Major depression · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Health‐related quality of life Health Status Questionnaire Short Form (SF‐36) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Anxiety Brief Symptom Inventory (BSI) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Withdrawal from dialysis · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Withdrawal from intervention · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Spiritual practice vs usual care Death (any cause) · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive‐behavioural therapy vs usual care Anxiety Beck Anxiety Inventory (BAI) (median · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive‐behavioural therapy vs usual care Withdrawal from dialysis · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive‐behavioural therapy vs usual care Withdrawal from intervention · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Counselling vs usual care Major depression · people with ESKD Psychosocial interventions for preventing and treating depression in dialysis patients (2019) · Cochrane | no estimate extracted | NR | No studies |
Human albumin infusion plus furosemide vs glucose Quality of life · patients of all ages with oedema due to nephrotic syndrome Human albumin infusion for treating oedema in people with nephrotic syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Low dialysate [Na+] (< 138 mM) vs high dialysate [Na+] (> 140 mM) Antihypertensive medication · chronic HD Low dialysate sodium levels for chronic haemodialysis (2019) · Cochrane | no estimate extracted | NR | No studies |
Hypothermic machine perfusion vs static cold storage One year graft survival · deceased donor kidney transplantation Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation (2019) · Cochrane | no estimate extracted | NR | No studies |
Isothermal dialysate vs thermoneutral dialysate Death (all causes) · patients requiring haemodialysis Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease… (2019) · Cochrane | no estimate extracted | NR | No studies |
Isothermal dialysate vs thermoneutral dialysate Acute coronary syndrome · patients requiring haemodialysis Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease… (2019) · Cochrane | no estimate extracted | NR | No studies |